Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
-
Elżbieta Kimak
Abstract
Studies were carried out in 183 non-dialyzed, 123 hemodialysis, 81 continuous ambulatory peritoneal dialysis and 35 post-transplant patients and in 103 healthy subjects as a reference group. Lipids and apolipoprotein (apo)AI and apoB were determined using Roche kits. An anti-apoB antibody was used to separate apoB-containing apoCIII and apoE-triglyceride-rich lipoprotein (TRL) in the non-high-density lipoprotein (non-HDL) fraction from apoCIIInonB and apoEnonB in the HDL fraction in four groups of patients with chronic renal failure (CRF) and healthy subjects. Multivariate linear regression analysis was used to investigate the relationship between triglyceride (TG) or HDL-cholesterol (HDL-C) concentrations and lipoproteins. Dyslipidemia varied according to the degree of renal insufficiency, the type of dialysis and therapy regime in CRF patients. Lipoprotein disturbances were manifested by increased TG, non-HDL-C and TRL concentrations, and decreased HDL-C and apoAI concentrations, whereas post-renal transplant patients showed normalization of lipid and lipoprotein profiles, except for TG levels and total apoCIII and apoCIIInonB. The present study indicates that CRF patients have disturbed lipoprotein composition, and that hypertriglyceridemia and low HDL-C concentrations in these patients are multifactorial, being secondary to disturbed lipoproteins. The method using anti-apoB antibodies to separate apoB-containing lipoproteins in the non-HDL fraction from non-apoB-containing lipoproteins in HDL can be used in the diagnosis and treatment of patients with progression of renal failure or atherosclerosis. The variability of TG and HDL-C concentrations depends on the variability of TRL and cholesterol-rich lipoprotein concentrations, but the decreases in TG and increases in HDL-C concentrations are caused by apoAI concentration variability. These relationships, however, need to be confirmed in further studies.
References
1. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities study. Kidney Int 2000; 58:293–301.10.1046/j.1523-1755.2000.00165.xSuche in Google Scholar
2. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886–92.10.1161/01.CIR.102.16.1886Suche in Google Scholar
3. Rutkowski B, Szolkiewicz M, Korczyńska J, Sucajtys E, Stelmańska E, Nieweglowski T, et al. The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis 2003; 41(Suppl 1):S84–8.10.1053/ajkd.2003.50092Suche in Google Scholar
4. Kimak E, Solski J. ApoA- and ApoB-containing lipoproteins and Lp(a) concentration in non-dialized patients with chronic renal failure. Ren Fail 2002; 24:481–8.10.1081/JDI-120006775Suche in Google Scholar
5. Kimak E, Solski J, Janicka L, Książek A, Janicki K. Concentration of Lp(a) and other apolipoproteins in pre-dialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Clin Chem Lab Med 2000; 38:421–5.10.1515/CCLM.2000.061Suche in Google Scholar
6. Moberly JB, Attman P-O, Samuelsson O, Johansson A-C, Knight-Gibson C, Alaupovic P. Apolipoprotein CIII, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 1999; 25:258–62.10.1159/000057457Suche in Google Scholar
7. Lee DM, Knight-Gibson C, Samuelsson O, Attman P-O, Wang C-S, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61:209–18.10.1046/j.1523-1755.2002.00116.xSuche in Google Scholar
8. Samuelsson O, Attman P-O, Knight-Gibson C, Larsson R, Mulec H, Weiss HA, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998; 9:1482–8.10.1681/ASN.V981482Suche in Google Scholar
9. Attman P-O, Samuelsson JM, Moberly J, Johansson A-C, Ljungman S, Weiss LG, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55:1536–42.10.1046/j.1523-1755.1999.00375.xSuche in Google Scholar
10. Lee S-J, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with VLDL-containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003; 167:293–302.10.1016/S0021-9150(03)00007-8Suche in Google Scholar
11. Santo SMS, Rensen PCN, Goudriaan JR, Bensadoun A, Bovenschen N, Voshol PJ, et al. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res 2005; 46:1097–102.10.1194/jlr.C500007-JLR200Suche in Google Scholar PubMed
12. Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, De Barse MM, Boer J, et al. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 2004; 65:1064–75.10.1111/j.1523-1755.2004.00466.xSuche in Google Scholar PubMed
13. Schreier L, Gonzalez AI, Elbert A, Berg G, Wikinski R. Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients. Metabolism 2004; 53:1013–5.10.1016/j.metabol.2004.01.001Suche in Google Scholar PubMed
14. Huard K, Bourgeois P, Rhainds D, Falstrault L, Cohn JS, Brissette L. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells. Int J Biochem Cell Biol 2005; 37:1308–18.10.1016/j.biocel.2005.01.005Suche in Google Scholar PubMed
15. Charpentier D, Tremblay C, Rassart E, Rhainds D, Auger A, Milne RW, et al. Low- and high-density lipoprotein metabolism in HepG2 cells expressing various levels of apolipoprotein E. Biochemistry 2000; 39:16084–91.10.1021/bi001436uSuche in Google Scholar PubMed
16. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004; 15:1008–15.10.1097/01.ASN.0000117286.85443.7DSuche in Google Scholar PubMed
17. Lee J-Y, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, et al. Preβ high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res 2004; 45:716–28.10.1194/jlr.M300422-JLR200Suche in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Artikel in diesem Heft
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
